Pharmacological management of renal fibrotic disease.

about

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

P2860

Q24656131-ECE97765-5107-4113-BCCA-4359FAC7C1CB

P2860

Pharmacological management of renal fibrotic disease.

Item

http://www.wikidata.org/entity/Q36407348

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Pharmacological management of renal fibrotic disease.

@ast

Pharmacological management of renal fibrotic disease.

@en

type

Item

label

Pharmacological management of renal fibrotic disease.

@ast

Pharmacological management of renal fibrotic disease.

@en

prefLabel

Pharmacological management of renal fibrotic disease.

@ast

Pharmacological management of renal fibrotic disease.

@en

P1476

Pharmacological management of renal fibrotic disease.

@en

P2093

Hans-H Neumayer

http://www.w3.org/2001/XMLSchema#string

Jens Gaedeke

http://www.w3.org/2001/XMLSchema#string

P2860

Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta.

Efficacy and safety of benazepril for advanced chronic renal insufficiency.

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.

P304

377-386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.7.4.377

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Harm Peters

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16503810

http://www.w3.org/2001/XMLSchema#string

Pharmacological management of renal fibrotic disease.

about

P2860

P2860

Pharmacological management of renal fibrotic disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698